Prevention of cardiomyopathy in mouse models lacking the smooth muscle sarcoglycan-sarcospan complex.
暂无分享,去创建一个
K. Campbell | R. Cohn | R. Coral-Vázquez | S. Moore | M. Durbeej | S. Prouty | Sally J. Prouty | Ronald D. Cohn | Madeleine Durbeej | Steven A. Moore | Ramón Mauricio Coral-Vázquez | Kevin P. Campbell
[1] J. Mendell,et al. Expression of γ-Sarcoglycan in Smooth Muscle and Its Interaction with the Smooth Muscle Sarcoglycan-Sarcospan Complex* , 2000, The Journal of Biological Chemistry.
[2] K. Campbell,et al. Molecular basis of muscular dystrophies , 2000, Muscle & nerve.
[3] J. Towbin,et al. Mutations in the Human δ-Sarcoglycan Gene in Familial and Sporadic Dilated Cardiomyopathy, a Disease of the Cytoskeleton and Sarcolemma , 2000 .
[4] T. Negri,et al. Disruption of heart sarcoglycan complex and severe cardiomyopathy caused by β sarcoglycan mutations , 2000, Journal of medical genetics.
[5] J. Towbin,et al. Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. , 2000, The Journal of clinical investigation.
[6] K. Campbell,et al. Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. , 2000, Molecular cell.
[7] E. Mercuri,et al. Cardiomyopathy in Duchenne, Becker, and sarcoglycanopathies: A role for coronary dysfunction? , 1999, Muscle & nerve.
[8] J. Sanes,et al. ε-Sarcoglycan Replaces α-Sarcoglycan in Smooth Muscle to Form a Unique Dystrophin-Glycoprotein Complex* , 1999, The Journal of Biological Chemistry.
[9] K. Campbell,et al. Biochemical Characterization of the Epithelial Dystroglycan Complex* , 1999, The Journal of Biological Chemistry.
[10] K. Campbell,et al. Disruption of the Sarcoglycan–Sarcospan Complex in Vascular Smooth Muscle A Novel Mechanism for Cardiomyopathy and Muscular Dystrophy , 1999, Cell.
[11] K. Chien,et al. Complexity in simplicity: monogenic disorders and complex cardiomyopathies. , 1999, The Journal of clinical investigation.
[12] E. Hoffman,et al. Heart involvement in muscular dystrophies due to sarcoglycan gene mutations , 1999, Muscle & nerve.
[13] M. Martone,et al. Enteroviral protease 2A cleaves dystrophin: Evidence of cytoskeletal disruption in an acquired cardiomyopathy , 1999, Nature Medicine.
[14] M. Passos-Bueno,et al. A first missense mutation in the delta sarcoglycan gene associated with a severe phenotype and frequency of limb-girdle muscular dystrophy type 2F (LGMD2F) in Brazilian sarcoglycanopathies. , 1998, Journal of medical genetics.
[15] M. Passos-Bueno,et al. Autosomal recessive limbgirdle muscular dystrophy, LGMD2F, is caused by a mutation in the δ–sarcoglycan gene , 1996, Nature Genetics.
[16] F. Apple,et al. Cardiac troponin-I is not expressed in fetal and healthy or diseased adult human skeletal muscle tissue. , 1995, Clinical chemistry.
[17] F. Cecchi,et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. , 1994, The American journal of cardiology.
[18] M. Sole,et al. Verapamil ameliorates the clinical and pathological course of murine myocarditis. , 1992, Journal of Clinical Investigation.
[19] P E Leaverton,et al. Prevalence and mortality rate of congestive heart failure in the United States. , 1992, Journal of the American College of Cardiology.
[20] L. Politano,et al. The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. , 1990, International journal of cardiology.
[21] R. Bonow,et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. , 1989, Circulation.
[22] E. Sonnenblick,et al. Prevention of hereditary cardiomyopathy in the Syrian hamster with chronic verapamil therapy. , 1988, Journal of the American College of Cardiology.
[23] H. Hayashi,et al. Effects of verapamil on experimental cardiomyopathy in the Bio 14.6 Syrian hamster. , 1987, Journal of the American College of Cardiology.
[24] R. Bonow,et al. Myocardial ischemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. , 1985, Circulation.
[25] M. Bourassa,et al. Pathogenesis of chest pain in patients with cardiomyopathies and normal coronary arteries. , 1983, International journal of cardiology.
[26] W. Kübler,et al. Coronary dilatory capacity in idiopathic dilated cardiomyopathy: analysis of 16 patients. , 1983, The American journal of cardiology.
[27] M. Hiroe,et al. Comparison of Thallium‐201 Scanning in Idiopathic Dilated Cardiomyopathy and Severe Coronary Artery Disease , 1982, Circulation.